Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

terferon gamma-1b) revenue of $6.0 million, compared with $8.5 million in the same quarter of 2008, a decrease of approximately 29%, reflecting lower off-label physician prescriptions of Actimmune for the treatment of IPF, which InterMune does not promote.

Research and development (R&D) expenses in the first quarter of 2009 were $24.4 million compared with $27.2 million in the first quarter of 2008, a decrease of approximately 10%, reflecting completion of the CAPACITY clinical trials in late 2008. General and administrative (G&A) expenses were $8.5 million in the first quarter of 2009, compared with $7.5 million in the same period a year earlier, an increase of approximately 13%, attributed to legal fees associated with a Department of Justice (DOJ) action against a former InterMune executive covered by an indemnification agreement, and costs related to preparation for the anticipated commercialization of pirfenidone.

InterMune additionally reported that first quarter 2009 expenses included a milestone payment of $13.5 million for pirfenidone that was expensed as Acquired Research and Development Milestone. The milestone payment was made in accordance with the pirfenidone purchase agreement and InterMune's decision to submit NDA and MAA filings for pirfenidone.

InterMune also reported expenses of $0.6 million recorded as Restructuring Charges related to a reduction in force in February 2009.

As of March 31, 2009, InterMune had cash, cash equivalents and available-for-sale securities of approximately $175.2 million, compared with $154.7 million at December 31, 2008. The March 31, 2009 balance includes net proceeds of approximately $63.4 million from a follow-on public offering of 4,025,000 shares of common stock completed on February 19, 2009. InterMune made an accelerated payment in the quarter to the DOJ of $4.4 million related to the company's recent financing event. The Ma
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... GAITHERSBURG, Md., Oct. 28 Sirnaomics, Inc., ... has received an SBIR,(small business innovation research) ... of Health (NIH). Sirnaomics, Inc., a,biopharmaceutical company ... advancing,RNA interference (RNAi) Technology for novel targeted ...
... Colo., Oct. 28 N30 Pharma (N30), a,biopharmaceutical ... drugs that regulate nitric oxide bioavailability,announced today that ... Board of,Directors., N30 will use proceeds from ... Fibrosis and expand its discovery and preclinical,research in ...
... Flavor Ingredient Achieves ... Collaboration Milestone, SAN DIEGO, CA - ... company focused on using proprietary,technologies to discover and develop novel flavor ... it has,received a payment from The Coca-Cola Company (NYSE: KO ...
Cached Biology Technology:Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 2Sirnaomics Receives SBIR Grant from NCI For Its Multi-Targeted Cancer siRNA Therapeutics 3N30 Pharma Announces Financing, Expansion of Board 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 2SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY 3
(Date:4/15/2014)... know as early as 2020 how high sea levels ... team of researchers including Florida International University scientist Rene ... Science Foundation,s (NSF) Florida Coastal Everglades Long-Term Ecological Research ... in ecosystems from coral reefs to deserts, mountains to ... sea level rise is one of the most certain ...
(Date:4/15/2014)... Mass. Diana Lados, associate professor of ... and founding director of the university,s Integrative ... major career achievement awards from leading engineering ... Detroit, SAE International, a global association of ... experts in the automotive, aerospace, and commercial ...
(Date:4/15/2014)... at UC San Diego have succeeded in visualizing ... responsible for growth and resistance to drought. The ... to determine how the hormone helps plants respond ... the continuing increase in the atmosphere,s carbon dioxide, ... appears in the April 15 issue of the ...
Breaking Biology News(10 mins):Long-term predictions for Miami sea level rise could be available relatively soon 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5Biologists develop nanosensors to visualize movements and distribution of plant hormone 2
... A new research initiative launched today (09 February) aims ... to deliver bigger yields of better quality fruits and ... Fruits and vegetables are a vitally important part ... will be crucial if we are to ensure global ...
... A new study by psychologists at The University of ... finger food are more likely to develop healthier food preferences ... those who are spoon-fed pureed food. The research just ... the impact of weaning style on food preferences and Body ...
... legendary for their effortless swimming. George Lauder from Harvard ... human engineers, but more recently attention has focused on ... razor sharp tooth-like scales, called denticles, the skin is ... ball, disturbing the flow of water over the surface ...
Cached Biology News:£7 public funding available for research to deliver better fruit and vegetables 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 2Baby knows best! Study shows baby-led weaning promotes healthy food preferences 3Amazing skin gives sharks a push 2
Activating Agents, 7-azabenzotriazol-1-yloxy-tris-(pyrrolidino)phosphonium hexafluorophosphate...
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
...
Biology Products: